Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy

Photodiagnosis and Photodynamic Therapy

Volumn 12, Issue 4, 2015, Pages 561-566

  Kanick, S C ^a,b   Davis, S C ^a,b   Zhao, Y ^a   Sheehan, K L ^b   Hasan, T ^c   Maytin, E V ^c,d   Pogue, B W ^a,b,c   Chapman, M S ^b  

^a DARTMOUTH COLLEGE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Actinic keratosis; Optical dosimetry; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; BIOLOGICAL MARKER; PROTOPORPHYRIN; PHOTOSENSITIZING AGENT;

ACTINIC KERATOSIS; ARTICLE; DIODE LASER; ERYTHEMA; FEASIBILITY STUDY; FLUORESCENCE SPECTROSCOPY; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; PAIN; PAIN ASSESSMENT; PHOTODYNAMIC THERAPY; PHOTODYNAMIC THERAPY DEVICE; PREDICTIVE VALUE; PRIORITY JOURNAL; SPECTROPHOTOMETER; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE; BIOSYNTHESIS; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; KERATOSIS, ACTINIC; MALE; PHOTOCHEMOTHERAPY; PROCEDURES; SPECTROFLUOROMETRY;

AMINOLEVULINIC ACID; BIOMARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHEMA; FEMALE; HUMANS; KERATOSIS, ACTINIC; MALE; PAIN; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; SPECTROMETRY, FLUORESCENCE;

EID: 84955062072     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2015.10.006     Document Type: Article

References (42)

1. Feldman S.R., Fleischer A.B. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 2011, 87(4):201-207.
2. Gupta A.K., et al. Interventions for actinic keratoses. Cochrane Database Syst. Rev. 2012, 12:CD004415.
3. Pomerantz H., et al. Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol. 2015.
4. Kalisiak M.S., Rao J. Photodynamic therapy for actinic keratoses. DermatolClin. 2007, 25(1):15-23.
5. Jeffes E.W., et al. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J. Am. Acad. Dermatol. 2001, 45(1):96-104.
6. Jeffes E.W. Levulan: the first approved topical photosensitizer for the treatment of actinic keratosis. J Dermatolog Treat 2002, 13(Suppl 1):S19-23.
7. Stritt A., et al. Photodynamic therapy in the treatment of actinic keratosis. Photochem. Photobiol. 2008, 84(2):388-398.
8. Braathen L.R., et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J. Am. Acad. Dermatol. 2007, 56(1):125-143.
9. Patel G., Armstrong A.W., Eisen D.B. Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: a systematic review and meta-analysis. JAMA Dermatol. 2014, 150(12):1281-1288.
10. Piacquadio D.J., et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004, 140(1):41-46.
11. Tarstedt M., et al. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm. Venereol. 2005, 85(5):424-428.
12. Tschen E.H., et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br. J. Dermatol. 2006, 155(6):1262-1269.
13. Bissonnette R., et al. Short incubation photodynamic therapy with methylaminolevulinate and no occlusion for the treatment of actinic keratoses. J. Am. Acad. Dermatol. 2012, 67(6):1386-1387.
14. Braathen L.R., et al. Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses. J. Eur. Acad. Dermatol. Venereol. 2009, 23(5):550-555.
15. Touma D., et al. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch. Dermatol. 2004, 140(1):33-40.
16. Smith S., et al. Short incubation PDT versus 5-FU in treating actinic keratoses. J. Drugs Dermatol. 2003, 2(6):629-635.
17. Smits T., et al. Correlation between macroscopic fluorescence and protoporphyrin IX content in psoriasis and actinic keratosis following application of aminolevulinic acid. J. Investig. Dermatol. 2005, 125(4):833-839.
18. Warren C.B., et al. Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact application of 5-aminolevulinate. J. Biomed. Opt. 2010, 15(5):051607.
19. Piffaretti F., et al. Correlation between protoporphyrin IX fluorescence intensity, photobleaching, pain and clinical outcome of actinic keratosis treated by photodynamic therapy. Dermatology 2013, 227(3):214-225.
20. Kanick S.C., et al. Dual-channel red/blue fluorescence dosimetry with broadband reflectance spectroscopic correction measures protoporphyrin IX production during photodynamic therapy of actinic keratosis. J. Biomed. Opt. 2014, 19(7):75002.
21. Rick K., et al. Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood. J. Photochem. Photobiol. B 1997, 40(3):313-319.
22. Ibbotson S.H., et al. Characteristics of 5-aminolaevulinic acid-induced protoporphyrin IX fluorescence in human skin in vivo. Photodermatol. Photoimmunol. Photomed. 2006, 22(2):105-110.
23. Golub A.L., et al. The monitoring of ALA-induced protoporphyrin IX accumulation and clearance in patients with skin lesions by in vivo surface-detected fluorescence spectroscopy. Lasers Med. Sci. 1999, 14(2):112-122.
24. Robertson K., Rees J.L. Variation in epidermal morphology in human skin at different body sites as measured by reflectance confocal microscopy. Acta Derm. Venereol. 2010, 90(4):368-373.
25. Willey A., Anderson R.R., Sakamoto F.H. Temperature-modulated photodynamic therapy for the treatment of actinic keratosis on the extremities: a pilot study. Dermatol. Surg. 2014, 40(10):1094-1102.
26. Anand S., et al. Biomodulatory approaches to photodynamic therapy for solid tumors. Cancer Lett. 2012, 326(1):8-16.
27. Juzeniene A., et al. Temperature effect on accumulation of protoporphyrin IX after topical application of 5-aminolevulinic acid and its methylester and hexylester derivatives in normal mouse skin. Photochem. Photobiol. 2002, 76(4):452-456.
28. Tyrrell J., Campbell S.M., Curnow A. The effect of air cooling pain relief on protoporphyrin IX photobleaching and clinical efficacy during dermatological photodynamic therapy. J. Photochem. Photobiol. B 2011, 103(1):1-7.
29. Gerritsen M.J., et al. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology 2009, 218(3):193-202.
30. Akilov O.E., et al. Prospects for the use of differentiation-modulating agents as adjuvant of photodynamic therapy for proliferative dermatoses. J. Dermatol. 2008, 35(4):197-205.
31. Choudry K., et al. The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy. Br. J. Dermatol. 2003, 149(1):124-130.
32. Anand S., et al. Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin. Cancer Res. 2009, 15(10):3333-3343.
33. Anand S., et al. Vitamin D3 enhances the apoptotic response of epithelial tumors to aminolevulinate-based photodynamic therapy. Cancer Res. 2011, 71(18):6040-6050.
34. Tyrrell J., Campbell S., Curnow A. Protoporphyrin IX photobleaching during the light irradiation phase of standard dermatological methyl-aminolevulinate photodynamic therapy. Photodiagnosis Photodyn. Ther. 2010, 7(4):232-238.
35. Tyrrell J.S., Campbell S.M., Curnow A. The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome. Lasers Surg. Med. 2010, 42(7):613-619.
36. Attili S.K., Dawe R., Ibbotson S. A review of pain experienced during topical photodynamic therapy-our experience in Dundee. Photodiagnosis Photodyn. Ther. 2011, 8(1):53-57.
37. Fabricius S., et al. The relation between methyl aminolevulinate concentration and inflammation after photodynamic therapy in healthy volunteers. Photochem. Photobiol. Sci. 2013, 12(1):117-123.
38. Brooke R.C., et al. Prostaglandin E2 and nitric oxide mediate the acute inflammatory (erythemal) response to topical 5-aminolaevulinic acid photodynamic therapy in human skin. Br. J. Dermatol. 2013, 169(3):645-652.
39. Ibbotson S.H. The acute inflammatory response to photodynamic therapy. Br. J. Dermatol. 2013, 169(3):491-492.
40. Warren C.B., et al. Pain associated with aminolevulinic acid-photodynamic therapy of skin disease. J. Am. Acad. Dermatol. 2009, 61(6):1033-1043.
41. Gholam P., et al. Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. J. Am. Acad. Dermatol. 2010, 63(2):213-218.
42. Kolde G. Follow-up analysis of the efficacy of photodynamic therapy in actinic keratosis. Br. J. Dermatol. 2013, 169(5):1156.